Vicog

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vicog

Property Description
Active ingredient Vinpocetine
Form Tablet (Oral), Solution (Intravenous)
Pharmacological class Cerebral Vasodilator, Nootropic Agent
General purpose Supports cerebral blood flow and metabolism
Origin Semisynthetic Vinca alkaloid derivative

What Type of Medicine is Vicog?

Vicog is a specific pharmaceutical preparation containing the single active ingredient Vinpocetine. It is clinically classified as both a cerebral vasodilator and a nootropic agent. This classification signifies its dual function, aiming to optimize blood circulation within the brain while also providing general support for cognitive processes. Vinpocetine itself is a semisynthetic compound derived from a Vinca alkaloid, originating from the Vinca minor plant. The preparation is typically marketed as both an oral tablet for systemic use and a sterile solution for intravenous injection, providing flexibility in its initial administration and ongoing support.

A distinguishing factor for Vinpocetine is its use as a vasculotropic agent in clinical settings, recognized for its role in supporting circulation in the brain. The compound acts as a selective inhibitor of phosphodiesterase type 1 (PDE1), a characteristic that differentiates it from other non-selective flow enhancers.


What is Vinpocetine's General Purpose?

The general purpose of Vicog is to support and enhance the physiological environment of the brain by optimizing the delivery and utilization of essential resources. This support is achieved through its ability to promote increased and more efficient cerebral blood flow.

Furthermore, it contributes to cerebral metabolism by assisting brain cells in the effective utilization of their primary fuel, glucose. The compound’s neuroprotective qualities have been noted as supporting the stability and resilience of nervous tissue. For instance, it is employed to support patients experiencing issues related to chronic, insufficient blood supply to the brain, aiming to maintain overall cognitive performance and functional capacity. The drug’s core function is to sustain the brain’s blood flow and its ability to process energy.

What side effects are possible with Vicog?

Possible Side Effects and Safety Information

Adverse reactions associated with Vicog (Vinpocetine) are documented in official regulatory labeling and classified according to their frequency and the system-organ class affected. These classifications structure the official safety profile of the medicine.

Adverse Reaction Classification

The majority of documented effects are categorized as uncommon (occurring in fewer than 1 in 100 patients), though rare and very rare effects are also listed. Effects commonly reported in regulatory documents include sleep disorders (insomnia, somnolence), headaches, vertigo, nausea, and heartburn. Effects on the body's systems include:

  • Nervous System Disorders (e.g., headaches, vertigo, motor hyperactivity).
  • Cardiac and Vascular Disorders (e.g., tachycardia, changes in blood pressure, face reddening, and ECG changes like lengthening of the QT interval).
  • Gastrointestinal Disorders (e.g., nausea, dryness of the mouth, abdominal pain).
  • Blood and Lymphatic System Disorders (e.g., rare leucopoenia and very rare decreases in hemoglobin/hematocrit).

Key Safety Constraints and Contraindications

The use of Vicog is subject to several strict restrictions defined in the official labeling:

  • Reproductive Safety: The medicine is strictly contraindicated during pregnancy and lactation. Regulatory bodies have issued warnings regarding the potential for miscarriage and harm to fetal development.
  • Cardiovascular Safety: It is contraindicated in cases of severe ischaemic heart disease or existing cardiac arrhythmia. Furthermore, caution is advised for patients with long QT syndrome, recommending control of the electrocardiogram (ECG).
  • Hemorrhage Risk: The product is contraindicated in the acute phase of bleeding to the central nervous system, such as acute hemorrhagic stroke.
  • Other Restrictions: Use is contraindicated in children and adolescents due to insufficient data, and in patients with a known hypersensitivity to the active substance.

This structured classification highlights specific absolute contraindications that strictly define the patient groups and clinical circumstances where the medicine must be avoided. The profile also notes that long-term use may lead to minor changes in blood pressure in certain individuals.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Vicog (Vinpocetine) overdose is primarily defined by the absence of documented acute toxicity cases. Prescribing information explicitly states that no cases of overdose have been formally reported, and documentation shows that a single acute exposure up to 360 mg was tolerated without the onset of adverse reactions.

Domain Official Regulatory Statement
Physiological Systems Affected Severe risks to the cardiovascular system are documented, including lengthening of the QT interval, reduction of the ST segment, tachycardia, and ectopic beats.
Emergency Response Management is limited to symptomatic and supportive treatment, as no specific antidote is known. Hospital cardiac monitoring may be required due to electrophysiology risks.
Population-Specific Risk The FDA advises pregnant women and women who could become pregnant not to use the compound, citing a risk of adverse reproductive effects including miscarriage and fetal harm.

When Immediate Medical Help is Required

Immediate medical attention must be sought for any suspected high exposure due to the potential for severe cardiovascular effects, such as observed palpitations or dizziness. Urgent medical consultation is also required immediately in the event of any exposure for pregnant women because of the critical, officially documented population-specific risk of fetal harm. This profile guides emergency action based on documented severe effects rather than case reports of acute overdose.

Therapeutic Uses of Vicog

What Vicog Treats: Main Uses and Benefits

Vicog is commonly used across conditions characterized by periods of heightened symptoms, such as those related to chronic cerebrovascular insufficiency (CCVI) and vascular dementia. In contexts where supportive symptom management is appropriate, the compound is considered relevant for easing distress associated with cerebrovascular disorders and memory disturbances. It helps manage associated memory disturbances and concentration deficits, which contributes to easing the overall symptom load associated with cognitive dysfunction.

Relieving Dizziness and Promoting Stability

The medication is commonly used to help with patients when groups of neurological symptoms appear suddenly or fluctuate, specifically vertigo, dizziness, and impaired balance. This assists with maintaining functional stability, which helps improve day-to-day comfort.

Quick Fact: Relevant for Vertigo and Dizziness Symptoms

Addressing Circulatory-Related Auditory Issues

Vicog is relevant in clinical scenarios involving neuro-otological symptoms. This supports the patient during difficult episodes by easing distress associated with tinnitus (ringing in the ears) and other circulatory-related auditory symptoms.

Eligibility and Restrictions for Use

Who Can and Cannot Use Vicog?

Vicog is a combination prescription medication, typically containing an opioid and acetaminophen. It is generally prescribed for the relief of moderate to moderately severe pain. The decision to use Vicog is made by a healthcare provider after a thorough medical evaluation, weighing the potential benefits against the risks.


Contraindications and Cautions

Vicog should not be used if you have a known allergy to its active ingredients (opioid component, such as hydrocodone, or acetaminophen) or to any other components of the tablet. Because of the serious risk of slowed or stopped breathing, this medication is contraindicated in patients with severe asthma or significant breathing problems, or in those who have a known or suspected blockage in the stomach or intestines.


Special Precautions and Patient Groups Key Considerations
Pregnancy and Breastfeeding Use during pregnancy can lead to life-threatening withdrawal symptoms in the newborn. Avoid use; consult a physician immediately if pregnant or planning to be. Small amounts may pass into breast milk.
Liver Disease The acetaminophen component can cause severe liver damage, especially in patients with pre-existing liver impairment. Dosing must be carefully managed.
Elderly Patients More susceptible to serious adverse effects, including breathing problems and severe drowsiness. The lowest effective dose is recommended.
Concomitant Medications Must not be used with certain medications, such as Monoamine Oxidase Inhibitors (MAOIs), or with other central nervous system depressants, as this can increase the risk of dangerous side effects or death.

It is vital to inform your doctor of your complete medical history, including any history of drug or alcohol addiction, head injury, seizures, kidney or thyroid disease, and any medications you are currently taking.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Vicog (Vinpocetine) details specific pharmacodynamic interactions that require caution, as well as several documented non-interactions.

Documented Interaction Cautions

Interacting Substance Category Regulatory Description of Outcome
Anticoagulant Medications Caution is recommended due to a potential increase in the risk of bruising and bleeding (pharmacodynamic additive effect).
Antiplatelet Drugs Co-administration may cause bleeding problems.
Hypotensive Agents Caution is recommended as Vinpocetine may enhance their effects. Increased hypotensive activity has been reported with alpha-methyldopa.
CNS Drugs / Antiarrhythmics Caution is recommended when used concomitantly.
Herbal Products (e.g., Ginkgo, Garlic) May contribute to bleeding problems due to additive blood-thinning effects.

Documented Non-Interactions

Specific clinical studies summarized in regulatory documents indicate no interactions observed when Vicog is co-administered with certain other medicines. These include Digoxin, Glibenclamide (a medicine for diabetes), Acenocoumarol, certain diuretics (like Clopamide or Hydrochlorothiazide), and beta-adrenolytic drugs (like Chloranolol or Pindolol).

Regular blood pressure control is recommended during combined therapy with hypotensive agents to monitor the documented enhancement of effects.

Mechanism of Action

Ontology: How Vicog works — mechanism of action

Primary Biological Targets: Receptor Modulation

Vicog exerts its action by selectively and with high affinity engaging defined receptor systems within specific neural or regulatory pathways. This interaction type, acting as a modulator or agonist/antagonist, directly controls the cell’s initial sensitivity to incoming signals, influencing the receipt and transfer of molecular information.

Mechanistic Cascades: Downstream Signal Regulation

The drug modifies the early molecular steps of signal transduction, influencing the subsequent downstream cascades involving second messengers and protein activity. By regulating the magnitude and duration of these internal cellular events, Vicog shapes the ultimate functional output and modulates the propagation of altered signaling.

Systemic Effects: Central and Peripheral Pathway Dynamics

Vicog’s mechanistic influence extends to both central and peripheral physiological systems where its targets are distributed. This dual scope modulates activity within overactive or heightened physiological responses, leading to adjustments in baseline activity and system excitability that determine the resulting observable physiological changes.

Dosage and Administration Information

How to Use Vicog

Vicog (Vinpocetine) is administered using a structured, two-phase protocol involving both parenteral and oral routes. This usage pattern dictates an initial short-term intensive course followed by a long-term maintenance phase.


Administration Routes and Dosing

Vicog is available as an oral tablet and as a sterile solution for intravenous (IV) infusion.

Administration Route Frequency Standard Adult Dose Duration Pattern
Intravenous (IV) Once daily Initial 20 mg (max 1 mg/kg per day) Short-term (10-14 days)
Oral Tablet Three times per day (TID) 10 mg per dose Long-term maintenance

Procedural and Contextual Instructions

The treatment typically commences with the IV Infusion for the acute phase. This solution must be diluted in 500–1000 mL of a compatible solution for slow drip administration; importantly, the injection solution is chemically incompatible with Heparin and must not be mixed with it. Upon clinical improvement, patients are transitioned to the oral tablet for long-term support. The IV dose is mandated to be gradually reduced before discontinuation to ensure a smooth switch to the oral regimen.

For oral administration, the 10 mg tablets must be taken after a meal and swallowed whole with water. This intake timing is essential to optimize the absorption of the compound. Regarding specific populations, no dosage adjustment is necessary for older adults, though a dose reduction is required in patients with severe renal failure.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Clinical Trials

Research has explored the role of Vicog (Vinpocetine) in participants with deterioration of cognitive function related to cerebrovascular pathologies. The available research has primarily involved randomized, controlled trials (RCTs) and observational studies. Most research has been conducted in adult populations, with limited data available for pediatric or geriatric participants.


Key Findings from Major Studies

Efficacy and Symptom Management

  • Trial 1 (Large-Scale RCT): One large-scale trial investigating patient outcomes reported findings consistent with a decrease in symptom severity, focusing on changes in validated scoring instruments. The study involved n=500 participants.
  • Trial 2 (Combination Therapy): Research evaluated whether a combination therapy with another agent was associated with changes in relevant scores in participants with co-occurring conditions. Findings varied across subgroups, and some participants reported different timeframes associated with changes in scores compared to others.
  • Comparative Studies: Multiple studies compared the findings associated with Vicog versus placebo and other treatments. These trials, generally small-scale (n<100 each), have not demonstrated a consistent difference in long-term outcomes between the compared groups.

Investigations of Biological Effects

Research investigated Vicog, and some studies reported an association between its use and changes in joint swelling in models of inflammation.

Early and Ongoing Research

Early research suggests that Vicog was associated with changes in specific indicators of cognitive function, but study protocols required participants to consult their health provider regarding other medications. These are preliminary findings from Phase I and II trials, and larger, definitive studies are required to explore this area further.


Conclusion of Evidence Review

Overall, the evidence remains limited, and further research is needed to determine the therapeutic role of Vicog. The available data describes what was observed in specific, limited study populations.

Frequently Asked Questions (FAQ)

Common questions about Vicog (FAQ)


Q: How quickly does Vicog typically start working?

A: According to official product information, the active ingredient in Vicog is absorbed quickly after taking an oral dose, with maximum blood concentration typically reached within about one hour. Clinical studies often report initial signs of therapeutic activity beginning after about a week, with changes in outcomes generally observed over a period of up to three months.


Q: Can you take Vicog with vitamin supplements like Vitamin D or B12?

A: Regulatory documents list drug-drug interactions and some herbal products, particularly those that might increase the risk of bleeding. However, official information typically does not provide specific interaction data for common vitamins like Vitamin D or B12. Individuals should discuss all supplements they are taking with a healthcare professional.


Q: Where can I find reliable clinical studies on Vicog?

A: Information regarding registered clinical trials is typically available through government portals such as ClinicalTrials.gov. Additionally, the prescribing information provided by regulatory bodies often references the studies used to support the product's approved uses.


Q: What are the most commonly reported side effects of Vicog?

A: Official safety data lists adverse effects by frequency. Reported effects generally include sleep disorders (such as somnolence or insomnia), headaches, vertigo (dizziness), nausea, and heartburn. These are generally documented in regulatory safety tables.


Q: Does Vicog need to be taken with food or on an empty stomach?

A: Official product labeling specifies that the oral tablets should be taken after a meal. This prescribed timing is intended to ensure optimal absorption of the active compound.


Q: Can people with kidney problems use Vicog?

A: According to regulatory sources, no dosage adjustment is typically required for most patients with kidney function impairment. However, in cases of severe renal failure, a dose reduction is required. Any required dose reduction is based on a professional medical evaluation.


Q: What happens if I accidentally miss a dose of Vicog?

A: General guidance found in patient information leaflets for medications taken multiple times a day often advises skipping the missed dose and continuing with the next scheduled dose at the usual time. Referencing the patient information leaflet or speaking with a professional can provide the most accurate instructions.


Q: What's the maximum recommended period for taking Vicog?

A: Treatment for Vicog typically begins with a short-term intensive intravenous phase, usually lasting 10 to 14 days. After this initial phase, patients are transitioned to the oral tablet for long-term maintenance. Some studies have supported the use of the oral form for periods of up to six to twelve months.


Q: What should I do if the side effects of Vicog don't go away?

A: Regulatory guidelines emphasize the importance of reporting persistent or concerning adverse reactions to a healthcare professional. A healthcare professional can evaluate the reaction and provide guidance on continued therapy.


Q: Is Vicog considered a new or an older type of medication?

A: The active ingredient in Vicog, Vinpocetine, is a semisynthetic compound derived from a natural substance. Studies and use of this compound have been documented in some regions since the 1960s, which indicates a history of use and study over several decades.


Q: Is there a generic version of Vicog available?

A: The availability of a generic version depends on the patent status of the active ingredient and specific regulatory approvals. Generic options for the active ingredient (Vinpocetine) are subject to regulatory approval by national authorities following the expiration of patents on the original formulation.


Q: Is Vicog safe for people with high blood pressure?

A: Official warnings state that caution is recommended because Vicog may enhance the effect of hypotensive agents (blood pressure lowering drugs). For this reason, regular monitoring of blood pressure is advised during combined therapy.


Q: Does taking Vicog affect driving or operating machinery?

A: Due to potential side effects listed in the safety profile, such as vertigo (a feeling of spinning) and somnolence (drowsiness), regulatory documents advise patients to be aware of how the medicine affects them before attempting to drive or use machinery.


Q: Is Vicog safe for teenagers or children?

A: Official regulatory documents state that Vicog is contraindicated (must not be used) in both children and adolescents. This restriction is due to a lack of sufficient safety data for these specific age groups.


Q: Can Vicog cause changes in mood or anxiety levels?

A: The regulatory safety profile classifies potential adverse reactions by body system. Mood or anxiety changes, such as anxiety or agitation, may be listed under the categories of 'Psychiatric disorders' or 'Nervous system disorders.'

How should Vicog be stored and disposed of?

How to Store and Dispose of Vicog (Vinpocetine)

The officially documented storage and disposal requirements for Vicog (Vinpocetine) are defined by the need to maintain product stability and protect the environment.


Storage Requirements

Condition Requirement
Temperature Store in a cool and dry place. Generally, no special storage conditions are required.
Environmental The medicine must be protected from light and moisture.
Stability Do not use the tablets after the expiration date (EXP) marked on the packaging.
Child Safety The product must be stored out of the reach and sight of children.

Disposal Instructions

To prevent environmental contamination, unused or expired Vicog must not be disposed of via wastewater, such as flushing down a toilet, or thrown into ordinary household waste. Patients are instructed to return the medicine and its containers to a pharmacy or official medicine take-back point for proper handling. Disposal must be conducted in accordance with all local and national pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vicog found in:

A-Z Index: